Cytokine changes during rituximab therapy in HIV-associated multicentric Castleman disease

Blood

Volumn 113, Issue 19, 2009, Pages 4521-4524

  Bower, Mark ^a   Veraitch, Ophelia ^b   Szydlo, Richard ^b   Charles, Peter ^b   Kelleher, Peter ^a   Gazzard, Brian ^a   Nelson, Mark ^a   Stebbing, Justin ^a,b,c  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^c CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CD19 ANTIGEN; CD20 ANTIBODY; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 5; INTERLEUKIN 6; MONOCLONAL ANTIBODY; RITUXIMAB; ANTINEOPLASTIC AGENT; CD20 ANTIGEN;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; B LYMPHOCYTE; CELL POPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG MECHANISM; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENT CELL; MALE; MORTALITY; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REMISSION; VIRUS LOAD; BLOOD; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; PATHOGENICITY; PROGNOSIS; VIROLOGY;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; CYTOKINES; GIANT LYMPH NODE HYPERPLASIA; HIV INFECTIONS; HIV-1; HUMANS; PROGNOSIS; VIRAL LOAD;

EID: 66549100751     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-12-197053     Document Type: Article

References (25)

1. Stebbing J, Pantanowitz L, Dayyani F, Sullivan RJ, Bower M, Dezube BJ. HIV-associated multicentric Castleman's disease. Am J Hematol. 2008;83:498-503.
2. Oksenhendler E, Duarte M, Soulier J, et al. Multicentric Castleman's disease in HIV infection: a clinical and pathological study of 20 patients. AIDS. 1996;10:61-67. (Pubitemid 26016404)
3. Sullivan RJ, Pantanowitz L, Casper C, Stebbing J, Dezube BJ. HIV/AIDS: epidemiology, pathophysiology, and treatment of Kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease. Clin Infect Dis. 2008;47: 1209-1215.
4. Zhang YJ, Bonaparte RS, Patel D, Stein DA, Iversen PL. Blockade of viral interleukin-6 expression of Kaposi's sarcoma-associated herpesvirus. Mol Cancer Ther. 2008;7:712-720.
5. Moore PS, Chang Y. Kaposi's sarcoma-associated herpesvirus-encoded oncogenes and oncogenesis. J Natl Cancer Inst Monogr. 1998:65-71.
6. Corbellino M, Bestetti G, Scalamogna C, et al. Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood. 2001;98:3473-3475.
7. Gholam D, Vantelon JM, Al-Jijakli A, Bourhis JH. A case of multicentric Castleman's disease associated with advanced systemic amyloidosis treated with chemotherapy and anti-CD20 monoclonal antibody. Ann Hematol. 2003;82:766-768. (Pubitemid 38008844)
8. Ocio EM, Sanchez-Guijo FM, Diez-Campelo M, et al. Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena. Am J Hematol. 2005; 78:302-305. (Pubitemid 40471124)
9. Casquero A, Barroso A, Fernandez Guerrero ML, Gorgolas M. Use of rituximab as a salvage therapy for HIV-associated multicentric Castleman disease. Ann Hematol. 2006;85:185-187. (Pubitemid 43174275)
10. Flejsierowicz M, Ahmed MS, Kotov P, Cheng YC. Successful treatment of aggressive HIV-associated multicentric Castleman's disease: a case report. WMJ. 2008;107:191-194. (Pubitemid 351955867)
11. Bestawros A, Michel R, Seguin C, Routy JP. Multicentric Castleman's disease treated with combination chemotherapy and rituximab in four HIV-positive men: a case series. Am J Hematol. 2008; 83:508-511. (Pubitemid 351742803)
12. Gerard L, Berezne A, Galicier L, et al. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial. J Clin Oncol. 2007;25:3350-3356. (Pubitemid 47325622)
13. Bower M, Powles T, Williams S, et al. Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med. 2007; 147:836-839. (Pubitemid 351664423)
14. Powles T, Stebbing J, Montoto S, et al. Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease. Blood. 2007;110:4132-4133. (Pubitemid 350248476)
15. Wang SY, Weiner G. Complement and cellular cytotoxicity in antibody therapy of cancer. Expert Opin Biol Ther. 2008;8:759-768. (Pubitemid 351860205)
16. Bannerji R, Kitada S, Flinn IW, et al. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance. J Clin Oncol. 2003;21:1466-1471. (Pubitemid 46594097)
17. Newsom-Davis T, Bower M, Wildfire A, et al. Resolution of AIDS-related Castleman's disease with anti-CD20 monoclonal antibodies is associated with declining IL-6 and TNF-alpha levels. Leuk Lymphoma. 2004;45:1939-1941. (Pubitemid 39004072)
18. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5:e203.
19. Stebbing J, Bower M, Mandalia S, Nelson M, Gazzard B. Highly active anti-retroviral therapy (HAART)-induced maintenance of adaptive but not innate immune parameters is associated with protection from HIV-induced mortality. Clin Exp Immunol. 2006;145:271-276. (Pubitemid 44060117)
20. Drexler HG, Meyer C, Gaidano G, Carbone A. Constitutive cytokine production by primary effusion (body cavity-based) lymphoma-derived cell lines. Leukemia. 1999;13:634-640. (Pubitemid 29195295)
21. Jones KD, Aoki Y, Chang Y, Moore PS, Yarchoan R, Tosato G. Involvement of interleukin-10 (IL-10) and viral IL-6 in the spontaneous growth of Kaposi's sarcoma herpesvirus-associated infected primary effusion lymphoma cells. Blood. 1999;94: 2871-2879. (Pubitemid 29477316)
22. Oksenhendler E, Carcelain G, Aoki Y, et al. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric Castleman disease in HIV-infected patients. Blood. 2000;96:2069-2073. (Pubitemid 30696233)
23. Ishii T, Tatekawa T, Koseto M, et al. A case of multicentric Castleman's disease demonstrating severe eosinophilia and enhanced production of interleukin-5. Eur J Haematol. 2003;70:115-118. (Pubitemid 36269558)
24. Nakagome K, Dohi M, Okunishi K, et al. IL-5-induced hypereosinophilia suppresses the antigen-induced immune response via a TGF-beta-dependent mechanism. J Immunol. 2007;179:284-294. (Pubitemid 46986544)
25. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283-2296. (Pubitemid 44837777)